Trial Profile
A 34-week Extension to a 28-week Multicenter, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study to Assess AIN457 Versus Placebo in Inducing and Maintaining Uveitis Suppression in Adults With Active, Non-infectious, Intermediate, Posterior, or Panuveitis Requiring Immunosuppression (INSURE Study)
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase III
Latest Information Update: 30 Sep 2020
Price :
$35
*
At a glance
- Drugs Secukinumab (Primary)
- Indications Intermediate uveitis; Panuveitis; Posterior uveitis
- Focus Therapeutic Use
- Acronyms INSURE
- Sponsors Novartis
- 24 Sep 2020 Status changed from discontinued to withdrawn prior to enrolment (Core study in non-infectious active uveitis was terminated).
- 18 Dec 2014 New trial record